Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme CorpfiledCriticalGenzyme Corp
Priority claimed from PCT/US2016/017210external-prioritypatent/WO2016130591A2/en
Publication of MA40818A1publicationCriticalpatent/MA40818A1/en
Publication of MA40818B2publicationCriticalpatent/MA40818B2/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Medicinal Preparation
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La présente invention concerne de nouveaux procédés d'administration de particules virales adéno-associées recombinées (raav) au système nerveux central d'un mammifère (p. Ex., l'homme). Selon certains aspects, les procédés impliquent l'administration des particules raav contenant un acide nucléique hétérologue au striatum et l'induction de l'expression de l'acide nucléique hétérologue dans au moins le cortex cérébral et le striatum du mammifère.The present invention relates to novel methods of delivering recombinant adeno-associated virus (raav) particles to the central nervous system of a mammal (eg, human). In some aspects, the methods involve administering the raav particles containing heterologous nucleic acid to the striatum and inducing expression of the heterologous nucleic acid in at least the cerebral cortex and striatum of the mammal.
MA40818A2015-02-102016-02-09
Improved delivery of viral particles to the striatum and cortex
MA40818B2
(en)
Exacerbation of Japanese encephalitis by CD11chi dendritic cell ablation is associated with an imbalance in regulatory Foxp3+ and IL-17+ CD4+ Th17 cells and in Ly-6Chi and Ly-6Clo monocytes
Interleukin 27, like interferons, activates JAK-STAT signaling and promotes pro-inflammatory and antiviral states that interfere with dengue and chikungunya viruses replication in human macrophages